• Mashup Score: 0
    Efanesoctocog alfa shows superior bleed protection in patients with severe hemophilia A - 2 year(s) ago

    A once-weekly dose of prophylactic efanesoctocog alfa conferred a significant reduction in annualized bleed rate compared with the use of prophylactic factor VIII agents, results of the pivotal phase 3 XTEND-1 study showed. Data from the trial, presented at International Society on Thrombosis and Haemostasis 2022 Congress, revealed that prophylactic efanesoctocog alfa (Sobi, Sanofi) offered

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      NEWS from #ISTH2022 A once-weekly dose of prophylactic efanesoctocog alfa conferred a significant reduction in annualized bleed rate compared with the use of prophylactic factor VIII agents, phase 3 XTEND-1 study shows. https://t.co/qBWSaeAXTH @UCSDHealth

  • Mashup Score: 0
    Fitusiran prophylaxis leads to 61% reduction in bleeds among people with hemophilia A or B - 2 year(s) ago

    Once-monthly prophylactic fitusiran resulted in significantly fewer bleeding episodes compared with episodic-based on-demand treatment among males with hemophilia A or B with or without inhibitors, according to results of a phase 3 study. Use of fitusiran (Sanofi) also led to significantly improved health-related quality-of-life scores, findings presented at International Society on Thrombosis

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      NEW from #ISTH2022 Once-monthly prophylactic fitusiran resulted in significantly fewer bleeding episodes compared with episodic-based on-demand treatment among males with hemophilia A or B with or without inhibitors, phase 3 data show. https://t.co/ZoISBpGgIg @sheba_medical

  • Mashup Score: 0
    International Society on Thrombosis and Haemostasis Congress 2022 - 2 year(s) ago

    Gili Kenet (Tel Aviv, Israel) presented results from the phase 3 ATLAS-PPX trial (NCT03549871) of the siRNA therapeutic fitusiran in men and boys 12 aged years and older with haemophilia A or B who have previously been treated with factor or bypassing agent (BPA). Patients continued on their previous treatment for 6 months, then switched to 80 mg subcutaneous fitusiran prophylaxis once per month…

    Source: The Lancet Haematology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancetHaem
      TheLancetHaem

      📢 Our Editor's highlights from #ISTH2022 @isth #bleedingdisorders #thombosis https://t.co/zDkyvlyMW8

  • Mashup Score: 0
    COVID-19 vaccination in patients with ITP - 2 year(s) ago

    Hanny Al-Samkari, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, comments on the safety of COVID-19 vaccination in patients…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      We spoke with @HannyAlSamkari at #ISTH2022 who shared some insights into the safety of COVID-19 vaccination in patients with immune thrombocytopenia. 🎥: https://t.co/1VmSiC2Rb4 @isth #HemOnc #RareDiseases

  • Mashup Score: 1
    Managing pregnant women with vWD - 2 year(s) ago

    Susan Halimeh, MD, Gerinnungszentrum Rhein-Ruhr, Duisburg, Germany, outlines the challenges associated with managing pregnant women with von Willebrand disease (vWD)….

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      We spoke with @HalimehSusan at #ISTH2022 on the challenges of managing pregnant women with von Willebrand disease: 🎥: https://t.co/6CB05jaUIA @isth #RareDiseases #HemOnc

Load More